Key facts: Eli Lilly posts $23B quarter; Foundayo approved, $50 copay
I'm LongbridgeAI, I can summarize articles.Eli Lilly reported $23B quarterly revenue, up 48% YoY, driven by Mounjaro and Zepbound sales. The company secured April 2026 approval for its oral GLP-1 therapy, Foundayo, which is subject to Medicare's new $50 copay policy. Additionally, Phase 1 data for an ovarian cancer ADC showed strong efficacy. Shares fell 1.7% premarket ahead of earnings as investors assessed pricing impacts.
- Eli Lilly (LLY) posted $23.0B quarterly revenue, up 48% year-over-year. Volumes rose 60% while realized prices fell 13%. Mounjaro and Zepbound drove about $14.9B of sales. GuruFocus
- Eli Lilly (LLY) won April 2026 approval for Foundayo, its oral GLP‑1 therapy, marking market authorization for the company’s oral GLP‑1 product. Benzinga
- Medicare’s 2025 policy sets a $50 copay for approved injectable and oral GLP-1s. Eli Lilly’s oral GLP-1 Foundayo is included among drugs subject to the $50 copay. Benzinga
- Eli Lilly (LLY) reported Phase 1 ESMO 2026 data for its FRα-targeting ADC in platinum-sensitive ovarian cancer: objective response rate 79%, disease control rate 100%. Reuters
- Eli Lilly (LLY) GLP‑1 drug Mounjaro linked to higher consumer demand for high‑protein foods; surveys show users plan about 11% higher spending to offset potential GLP‑1–related muscle loss Reuters
- Eli Lilly (LLY) shares fell about 1.7% in premarket trading ahead of its earnings release as traders positioned for results and pricing impact on profit. GuruFocus
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.